Growth through Enzymes and Microorganisms!
The health company focusing on enzymes and microorganisms benefits from growth in emerging markets!
The stock is currently in consolidation, which could establish the basis for the next upward wave!
Reading Time: 1 minute
Novonesis A/S is the second-largest publicly traded Danish company in the pharmaceutical and bioscience sector, with a market capitalization of approximately €25 billion, following Novo Nordisk. Fundamentally, the company reported strong numbers for the first nine months of the current fiscal year in November. Particularly noteworthy is the strong growth in emerging markets, which achieved organic growth of 12% in the first nine months. The areas of Food & Health as well as Planetary Health also showed robust growth rates. From a technical...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
